Eli Lilly 2008 Annual Report Download - page 2

On the Cover
Mark Wiley is a manager at Lilly who oversees
the contract manufacturing for several device
products, including an insulin pen called the
HumaPen® Luxura HD.™ Although the majority
of job roles that Mark has held in his 20-year
career at Lilly have, in some way, touched the
diabetes therapeutic area, he never could have
predicted the role that a Lilly insulin product
would one day play in his own life.
Nor could Mark have predicted, as he
packed up his laptop and left the offi ce to
enjoy the 2008 holiday break with his family,
that the job he would return to a week later
would have such new meaning.
On December 26, one day before her
14th birthday, Mark’s daughter, Paige, was
diagnosed with type 1 diabetes. Paige had
not been feeling well for awhile. She was
often thirsty and had little to no appetite.
Mark and his wife realized it was serious
when they weighed Paige on Christmas Eve
and discovered that she had lost 13 pounds
since October.
Upon learning Paige’s diagnosis, Mark
said they were shocked, but also relieved.
“Finding out that Paige had diabetes—we
knew—was a big deal. But we also saw it
as a blessing because we knew it could be
successfully treated.”
Paige was admitted to a local children’s
hospital, where she and her parents received
what Mark describes as a “crash course on
a completely new lifestyle.” But there was
one particular aspect of Paige’s insulin
treatment that Mark did feel comfortable
about—and that was using the HumaPen
Luxura HD to administer her injections. Given
that Mark oversees the manufacturing of this
device, he was more than familiar with how
the pen worked.
“I guess you could say that my job just
became very personal to me,” Mark said.
As for Paige, she has embraced her new
diagnosis and treatment regimen with a
maturity and courage beyond her years. And
she feels a lot better, too.
She’s also determined not to let diabetes
stand in her way. Just two days after leaving
the hospital, Mark delivered on a promise
he made before Paige’s diagnosis—he took
her rock climbing for her birthday. And
despite a fear of heights, Paige achieved her
goal that day—she successfully scaled her
way to the top.
Year in Review
1 Financial Highlights
2 Letter to Shareholders
7 Securing—Then Redefi ning—Lilly’s Future: A Tribute To Sidney Taurel
8 Innovation at Lilly: The Portfolio and the Pipeline
Financials
12 Review of Operations
16 Consolidated Statements of Operations
21 Consolidated Balance Sheets
22 Consolidated Statements of Cash Flows
23 Consolidated Statements of Comprehensive Income (Loss)
33 Segment Information
34 Selected Quarterly Data
35 Selected Financial Data
36 Notes to Consolidated Financial Statements
65 Management’s Reports
66 Report of Independent Registered Public Accounting Firm
Proxy Statement
68 Notice of 2009 Annual Meeting and Proxy Statement
69 General Information
73 Board of Directors
77 Highlights of the Company’s Corporate Governance Guidelines
82 Committees of the Board of Directors
82 Membership and Meetings of the Board and Its Committees
83 Directors’ Compensation
85 Directors and Corporate Governance Committee Matters
86 Audit Committee Matters
88 Compensation Committee Matters
89 Executive Compensation
111 Ownership of Company Stock
113 Items of Business To Be Acted Upon at the Meeting
122 Other Matters
123 Appen dix A
Corporate Information
124 Senior Management and Board of Directors
126 Corporate Information
127 Annual Meeting Admission Ticket
Eli Lilly and Company makes medicines that help people
live longer, healthier, and more active lives.
Integrity—Excellence—Respect for People
We promise to operate our business with absolute integrity
and earn the trust of all, set the highest standards for our
performance and for the performance of our products, and
demonstrate caring and respect for all those who share in
our mission and are touched by our work.
Improved Outcomes for Individual Patients
We will make a signifi cant contribution to humanity by
improving global health in the 21st century. Starting with the
work of our scientists, we will place improved outcomes for
individual patients at the center of what we do. We will listen
carefully to understand patient needs and work with health
care partners to provide meaningful benefi ts for the people
who depend on us.